Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01426412 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT01426412 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 69 participants.
The verdict
NCT01426412, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is a study in otherwise healthy Japanese and non-Japanese participants with elevated low density lipoprotein cholesterol (LDL-C). Following single doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body will be evaluated. Participants will remain in the study for approximately up to 6 months.
Interventions
- DRUG Placebo IV
- DRUG Placebo SC
- DRUG LY3015014 IV
- DRUG LY3015014 SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01426412
The ClinicalTrials.gov registry entry for NCT01426412 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo IV is the first listed.
NCT01426412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01426412 about?
NCT01426412 is a clinical study titled "A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol". This is a study in otherwise healthy Japanese and non-Japanese participants with elevated low density lipoprotein cholesterol (LDL-C). Following single doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body will be evaluated. Par...
What is the current status of trial NCT01426412?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2011-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01426412?
The interventions under investigation include: Placebo IV (DRUG), Placebo SC (DRUG), LY3015014 IV (DRUG), LY3015014 SC (DRUG).
Who is sponsoring clinical trial NCT01426412?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.